Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has ...

A drug against fungal infections in cancer patients can last twice as long in people with obesity, and may make chemotherapy ...

Understanding the investment thesis for Merck requires appreciating the importance of its blockbuster cancer drug, Keytruda, ...

A drug used by cancer patients may make chemotherapies less effective in patients with obesity — but many doctors are in the ...

Merck (MRK) will be in focus as company beats revenue forecasts despite in line earnings amid strong Keytruda sales in Q3 ...

MilliporeSigma continued its march of manufacturing investments this year, revealing plans to pump $76 million into expanding ...

Investing.com -- Merck and Co. (NYSE:MRK) has posted better-than-anticipated third-quarter profit thanks to solid demand for its crucial cancer treatment Keytruda, although the drugmaker warned of ...

Merck, a leading science and technology company, today announced a € 70 million expansion of its ADC manufacturing ...

Award recipients to receive in-kind technologies and services to accelerate therapeutics to market <li /> Merck e ...

Understanding the investment thesis for Merck requires appreciating the importance of its blockbuster cancer drug, Keytruda, to its finances. Right now, in the U.S. the drug is approved for 40 ...